A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

被引：102

作者：

Chevallier, P. ^{[1
,2
]}

Labopin, M. ^{[3
]}

Turlure, P. ^{[4
]}

Prebet, T. ^{[5
]}

Pigneux, A. ^{[6
]}

Hunault, M. ^{[7
]}

Filanovsky, K. ^{[8
]}

Cornillet-Lefebvre, P. ^{[9
]}

Luquet, I. ^{[9
]}

Lode, L. ^{[10
]}

Richebourg, S. ^{[10
]}

Blanchet, O. ^{[11
]}

Gachard, N. ^{[12
]}

Vey, N. ^{[5
]}

Ifrah, N. ^{[7
]}

Milpied, N. ^{[6
]}

Harousseau, J-L ^{[1
,2
]}

Bene, M-C ^{[13
]}

Mohty, M. ^{[1
,2
]}

Delaunay, J. ^{[1
,2
]}

机构：

[1] CHU Nantes, Serv Hematol Clin, F-44093 Nantes 01, France

[2] Univ Nantes, INSERM, U892, Nantes, France

[3] Univ Paris 06, Hop St Antoine, AP HP, EBMT Paris Off,ALWP, Paris, France

[4] CHU, Serv Hematol Clin, Limoges, France

[5] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[6] CHU, Serv Hematol Clin, Bordeaux, France

[7] CHU Angers, Serv Hematol Clin, Angers, France

[8] Kaplan Med Ctr, Dept Hematol, Rehovot, Israel

[9] CHU, Serv Biol Hematol, Reims, France

[10] CHU Nantes, Serv Biol Hematol, F-44093 Nantes 01, France

[11] CHU Angers, Serv Biol Hematol, Angers, France

[12] CHU, Serv Biol Hematol, Limoges, France

[13] CHU, Serv Biol Hematol, Nancy, France

来源：

LEUKEMIA | 2011年 / 25卷 / 06期

关键词：

AML; refractory; relapse; score; NPM1; FLT3; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; ELDERLY-PATIENTS; 1ST RELAPSE; MANAGEMENT; SURVIVAL; GEMTUZUMAB; TANDEM; INDEX;

D O I：

10.1038/leu.2011.25

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55 years, range: 19-70) receiving a combination of intensive chemotherapy+ Gemtuzumab as salvage regimen. Overall, 2-year event-free survival (EFS) and overall survival (OS) were 29 +/- 4% and 36 +/- 4%, respectively. Disease status (relapse < 12 months, including refractory patients), FLT3-ITD-positive status and high-risk cytogenetics were the three strongest independent adverse prognostic factors for OS and EFS in this series. We then defined three subgroups with striking different outcomes at 2 years: no adverse factor (favourable, N = 36): OS 58%, EFS 45%; one adverse factor (intermediate, N = 54): OS 37%, EFS 31%; two or three adverse factors (poor, N = 43): OS 12%, EFS 12% (P < 10(-4), P = 0.001). This new simplified Leukemia Prognostic Scoring System was then validated on an independent cohort of 111 refractory/relapsed AML patients. This new simplified prognostic score, using three clinical and biological parameters routinely applied, allow to discriminate around two third of the patients who should benefit from a salvage intensive regimen in the setting of refractory/relapsed AML patients. The other one third of the patients should receive investigational therapy. Leukemia (2011) 25, 939-944; doi:10.1038/leu.2011.25; published online 18 February 2011

引用

页码：939 / 944

页数：6

共 18 条

[1]

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype [J].

Boissel, N ;

Renneville, A ;

Biggio, V ;

Philippe, N ;

Thomas, X ;

Cayuela, JM ;

Terre, C ;

Tigaud, I ;

Castaigne, S ;

Raffoux, E ;

De Botton, S ;

Fenaux, P ;

Dombret, H ;

Preudhomme, C .

BLOOD, 2005, 106 (10) :3618-3620

[2]

Prognostic index for adult patients with acute myeloid leukemia in first relapse [J].

Breems, DA ;

Van Putten, WLJ ;

Huijgens, PC ;

Ossenkoppele, GJ ;

Verhoef, GEG ;

Verdonck, LF ;

Vellenga, E ;

De Greef, G ;

Jacky, E ;

Van der Lelie, J ;

Boogaerts, MA ;

Löwenberg, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1969-1978

[3]

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial [J].

Burnett, Alan K. ;

Hills, Robert K. ;

Milligan, Donald ;

Kjeldsen, Lars ;

Kell, Jonathan ;

Russell, Nigel H. ;

Yin, John A. L. ;

Hunter, Ann ;

Goldstone, Anthony H. ;

Wheatley, Keith .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :369-377

[4]

Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial [J].

Chevallier, P. ;

Fornecker, L. ;

Lioure, B. ;

Bene, M. C. ;

Pigneux, A. ;

Recher, C. ;

Witz, B. ;

Fegueux, N. ;

Bulabois, C-E ;

Daliphard, S. ;

Bouscary, D. ;

Vey, N. ;

Delain, M. ;

Bay, J-O ;

Turlure, P. ;

Bernard, M. ;

Himberlin, C. ;

Luquet, I. ;

Ifrah, N. ;

Harousseau, J-L .

LEUKEMIA, 2010, 24 (07) :1380-1385

[5]

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin [J].

Chevallier, P. ;

Prebet, T. ;

Pigneux, A. ;

Hunault, M. ;

Delaunay, J. ;

Perry, F. ;

Lode, L. ;

Richebourg, S. ;

Blanchet, O. ;

Vey, N. ;

Ifrah, N. ;

Milpied, N. ;

Blaise, D. ;

Harousseau, J-L ;

Mohty, M. .

LEUKEMIA, 2010, 24 (02) :467-469

[6]

Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia [J].

Chevallier, Patrice ;

Delaunay, Jacques ;

Turlure, Pascal ;

Pigneux, Arnaud ;

Hunault, Mathilde ;

Garand, Richard ;

Guillaume, Thierry ;

Avet-Loiseau, Herve ;

Dmytruk, Nathalia ;

Girault, Stephane ;

Milpied, Noel ;

Ifrah, Norbert ;

Mohty, Mohamad ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5192-5197

[7]

Gemtuzumab ozogamicin: is there room for salvage? [J].

Clarke, W. Thomas ;

Marks, PeterW. .

BLOOD, 2010, 116 (14) :2618-2619

[8]

Biology and management of relapsed acute myeloid leukaemia [J].

Craddock, C ;

Tauro, S ;

Moss, P ;

Grimwade, D .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) :18-34

[9]

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].

Doehner, Hartmut ;

Estey, Elihu H. ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Burnett, Alan K. ;

Dombret, Herve ;

Fenaux, Pierre ;

Grimwade, David ;

Larson, Richard A. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel A. ;

Sierra, Jorge ;

Tallman, Martin S. ;

Loewenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2010, 115 (03) :453-474

[10]

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Gattermann, Norbert ;

Germing, Ulrich ;

Sanz, Guillermo ;

List, Alan F. ;

Gore, Steven ;

Seymour, John F. ;

Dombret, Herve ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :562-569

← 1 2 →